Dianthus Therapeutics Inc. (DNTH) Stock Forecast & Price Target
Dianthus Therapeutics Inc. · NASDAQ
$109.26+1.16 (+1.07%)
15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 13 firms covering Dianthus Therapeutics Inc, 13 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. The target range is very wide, $65.00 to $200.00 (about 3.1x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $127.00 sits 16% above the current $109.26. The rating mix has stayed broadly stable, with Buy-side ratings easing from 13 to 12 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-1.13 next quarter toward $-4.62 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS13 ratings
Strong Buy
Strong Buy18%
Buy1292%
Hold00%
Sell00%
Strong Sell00%
Based on 13 analysts giving stock ratings to Dianthus Therapeutics Inc.
As of Sep, 12 of 12 firms rate DNTH a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
DNTH EPS & revenue forecast
EPS · NEXT QUARTER
$-1.13
Range $-1.36 – $-0.99 · 9 analysts · -21% YoY
Next period, 9 analysts expect Dianthus Therapeutics Inc. to earn $-1.13 a share (range $-1.36 – $-0.99), versus $-1.43 a year earlier. Full-year consensus is $-3.83, growing to $-4.62 the year after.
REVENUE · NEXT QUARTER
$302.8K
Range $0 – $1.0M · 9 analysts · +7% YoY
Revenue is expected to reach $302.8K (range $0 – $1.0M), +6.6% year-over-year. Full-year consensus is $1.8M, rising to $1.7M next year.
Top analysts covering Dianthus Therapeutics Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on DNTH.
#1
Yatin Suneja
Guggenheim · Rank #21
Buy
$200.00+83.0% to target
Overall win rate
53%
+ Follow
#2
Laura Chico
Wedbush · Rank #74
Buy
$122.00+11.7% to target
Overall win rate
44%
+ Follow
#3
Joel Beatty
Baird · Rank #80
Buy
$132.00+20.8% to target
Overall win rate
48%
+ Follow
#4
PS
Pete Stavropoulos
Cantor Fitzgerald · Rank #233
Buy
No targeton DNTH
Overall win rate
36%
+ Follow
#5
Swayampakula Ramakanth
HC Wainwright & Co. · Rank #252
Buy
$158.00+44.6% to target
Overall win rate
38%
+ Follow
DNTH stock forecast FAQ
What is DNTH's average 12-month price target?+
The 13 analysts with a live target average $127.00 for Dianthus Therapeutics Inc. over the next 12 months, ranging from a $200.00 high to a $65.00 low.
Is DNTH stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 13 analyst ratings, 13 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for DNTH?+
The Street-high target is $200.00 (Guggenheim), and the Street-low is $65.00 (Stifel). The average of all 13 active targets is $127.00.
How many Wall Street analysts cover DNTH?+
13 analysts have an active rating on Dianthus Therapeutics Inc., and 13 firms carry a live 12-month price target.
Who is the most accurate analyst covering DNTH?+
Among analysts who currently cover DNTH, Yatin Suneja of Guggenheim has the strongest overall Quantellect track record (Rank #21). Their current call is Buy with a $200.00 target.
What is Dianthus Therapeutics Inc.'s projected EPS for next quarter?+
The consensus estimate is $-1.13 per share (range $-1.36 – $-0.99) across 9 analysts. Full-year EPS is projected at $-3.83, rising to $-4.62 the following year.
How much revenue is Dianthus Therapeutics Inc. expected to report next quarter?+
Consensus revenue is $302.8K (range $0 – $1.0M). Full-year revenue is projected at $1.8M, growing to $1.7M next year.
Have analysts been upgrading or downgrading DNTH lately?+
As of Sep, 12 of 12 firms rate DNTH a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their DNTH calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
